

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

ENANTA PHARMACEUTICALS INC
Form SC 13G
January 07, 2015

January 7, 2015

Securities and Exchange Commission
100 F Street NE
Washington, DC 20549

RE: Schedule 13G
Enanta Pharmaceuticals Inc.
As of December 31, 2014

Gentlemen:

In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing beneficial ownership of 5% or more as of December 31, 2014 filed on behalf of Eagle Asset Management, Inc.

Very truly yours,

Damian Sousa
Vice President
Chief Compliance Officer
Enclosures

cc: Office of the Corporate Secretary
Enanta Pharmaceuticals Inc.
500 Arsenal Street
Watertown, MA 02472

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Enanta Pharmaceuticals Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

29251M106
(CUSIP Number)

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

Check the following box if a fee is being paid with this statement _____. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 5 Pages

CUSIP NO. 29251M106

13G

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Eagle Asset Management, Inc. 59-2385219

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) _____
(B) _____

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

State of Florida

NUMBER OF SHARES	5	SOLE VOTING POWER	
			1,109,644
BENEFICIALLY OWNED	6	SHARED VOTING POWER	- - -
AS OF			
DECEMBER 31, 2014	7	SOLE DISPOSITIVE POWER	
BY EACH			1,109,644
REPORTING PERSON WITH	8	SHARED DISPOSITIVE POWER	- - -

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,109,644

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_____]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

5.96%

12 TYPE OF REPORTING PERSON*

IA

*SEE INSTRUCTION BEFORE FILLING OUT!

Page 2 of 5 Pages

Item 1(a) Name of Issuer:

ENANTA PHARMACEUTICALS INC.

Item 1(b) Address of Issuer's Principal Executing Offices:

500 Arsenal Street
Watertown, MA 02472

Item 2(a) Name of Person Filing:

Eagle Asset Management, Inc.

Item 2(b) Address of Principal Business Office:

880 Carillon Parkway
St. Petersburg, Florida 33716

Item 2(c) Citizenship:

Florida

Item 2(d) Title of Class of Securities:

Common Stock

Item 2(e) CUSIP Number:

29251M106

Item 3 Type of Reporting Person:

(e) Investment Adviser registered under Section 203 of the Investment
Advisors Act of 1940

Page 3 of 5 Pages

Item 4 Ownership as of December 31, 2014

(a) Amount Beneficially Owned:

1,109,644 shares of common stock beneficially owned including:

No. of Shares

Eagle Asset Management, Inc.

1,109,644

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

(b) Percent of Class: 5.96%

(c) Deemed Voting Power and Disposition Power:

	(i)	(ii)	(iii)	(iv)
	Deemed	Deemed	Deemed	Deemed
	to have	to have	to have	to have
	Sole Power	Shared Power	Sole Power	Shared Power
	to Vote or	to Vote or	to Dispose	to Dispose
	to Direct	to Direct	or to	or to
	to Vote	to Vote	Direct the	Direct the
			Disposition	Disposition
Eagle Asset Management, Inc.	1,109,644	----	1,109,644	----

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

(___)

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

N/A

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

N/A

Page 4 of 5 Pages

Item 8 Identification and Classification of Members of the Group: N/A

Item 9 Notice of Dissolution of Group: N/A

Item 10 Certification:

By signing below I certify that to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 7, 2015

EAGLE ASSET MANAGEMENT, INC.

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

/s/ Damian Sousa

Damian Sousa
Vice President
Chief Compliance Officer

Page 5 of 5 Pages